Translations:GLP-1 receptor agonist/20/en

Approved

exenatide (brand names Byetta and Bydureon, manufactured by AstraZeneca), approved in 2005/2012
liraglutide (Victoza for diabetes, Saxenda for obesity, manufactured by Novo Nordisk), approved in 2010
albiglutide (Tanzeum, manufactured by GSK), approved in 2014
dulaglutide (Trulicity, manufactured by Eli Lilly), approved in 2014
lixisenatide (Lyxumia in Europe, Adlyxin in the United States, manufactured by Sanofi), approved in 2016
semaglutide (Ozempic and Rybelsus for diabetes, Wegovy for obesity, manufactured by Novo Nordisk), approved in 2017
tirzepatide (dual GLP-1 and GIP agonist; Mounjaro for diabetes, Zepbound for obesity, manufactured by Eli Lilly), approved in 2022